-
EP4327823
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4327823
| EP4327823 - ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 26.01.2024 Database last updated on 16.11.2024 | |
| Former | The international publication has been made Status updated on 28.10.2022 | Most recent event Tooltip | 27.06.2024 | Change: Validation states | published on 31.07.2024 [2024/31] | Applicant(s) | For all designated states Astellas Pharma Inc. 5-1, Nihonbashi-Honcho 2-Chome Chuo-ku Tokyo 103-8411 / JP | For all designated states National Cancer Center 1-1, Tsukiji 5-Chome Chuo-ku Tokyo 104-0045 / JP | [2024/09] | Inventor(s) | 01 /
TENDA, Yoshiyuki Tokyo 103-8411 / JP | 02 /
YURI, Masatoshi Tokyo 103-8411 / JP | 03 /
YAGI, Shigenori Tokyo 103-8411 / JP | 04 /
SATAKE, Yoshiki Tokyo 103-8411 / JP | 05 /
HIRAYAMA, Kazunori Tokyo 103-8411 / JP | 06 /
SHIRAI, Hiroki Tokyo 103-8411 / JP | 07 /
SASAKI, Hiroki Tokyo 104-0045 / JP | 08 /
CHIWAKI, Fumiko Tokyo 104-0045 / JP | 09 /
KOMATSU, Masayuki Tokyo 104-0045 / JP | [2024/09] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2024/09] | Application number, filing date | 22791768.9 | 21.04.2022 | [2024/09] | WO2022JP18350 | Priority number, date | JP20210072429 | 22.04.2021 Original published format: JP 2021072429 | [2024/09] | Filing language | JA | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022224997 | Date: | 27.10.2022 | Language: | JA | [2022/43] | Type: | A1 Application with search report | No.: | EP4327823 | Date: | 28.02.2024 | Language: | EN | [2024/09] | Search report(s) | International search report - published on: | JP | 27.10.2022 | Classification | IPC: | A61K39/395, A61P35/00, C07K16/46, C12N5/10, C12N1/15, C12N1/19, C12N1/21, C12N15/13, C12N15/62, C12N15/63, C12P21/08 | [2024/09] | CPC: |
A61P35/00 (EP,IL,KR,US);
A61K39/395 (IL);
C07K16/28 (EP,KR,US);
C07K16/2878 (EP,KR,US);
C07K16/00 (IL);
C07K16/46 (IL);
C12N15/62 (EP,IL);
C12N15/63 (IL);
C12N15/74 (IL);
C12N15/80 (IL);
C12N15/81 (IL);
C12N5/10 (IL);
A61K2039/505 (EP,KR,US);
C07K16/2809 (EP);
C07K2317/21 (KR);
C07K2317/31 (EP,KR,US);
C07K2317/51 (KR);
C07K2317/515 (KR);
C07K2317/622 (EP,KR,US);
C07K2317/64 (EP);
C07K2317/71 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/09] | Extension states | BA | 20.11.2023 | ME | 20.11.2023 | Validation states | MA | 20.11.2023 | Title | German: | BISPEZIFISCHER ANTI-CLDN4/ANTI-CD137-ANTIKÖRPER | [2024/09] | English: | ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY | [2024/09] | French: | ANTICORPS BISPÉCIFIQUE ANTI-CLDN4/ANTI-CD137 | [2024/09] | Entry into regional phase | 20.11.2023 | Translation filed | 20.11.2023 | National basic fee paid | 20.11.2023 | Search fee paid | 20.11.2023 | Designation fee(s) paid | 20.11.2023 | Examination fee paid | Examination procedure | 20.11.2023 | Examination requested [2024/09] | 16.05.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 13.03.2024 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2014132647 (JAPAN HEALTH SCIENCE FOUND [JP]); | [A]WO2019178356 (DANA FARBER CANCER INST INC [US]); | [A]WO2020011966 (F STAR BETA LTD [GB]); | [A]JP2020532572 ; | [A]JP2021510064 ; | by applicant | WO9007861 | US5225539 | US6180370 | US6596541 | WO2005035584 | JP5686953B | US9346873 | WO2021JP41839 |